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Background: Inhalation of chemotherapeutic drugs directly into the lungs augments the drug exposure to lung
cancers. The inhalation of free drugs however results in over exposure and causes severe adverse effect to normal
cells. In the present study, epidermal growth factor (EGF)-modified gelatin nanoparticles (EGNP) was developed to
administer doxorubicin (DOX) to lung cancers.
Results: The EGNP released DOX in a sustained manner and effectively internalized in EGFR overexpressing A549
and H226 lung cancer cells via a receptor-mediated endocytosis. In vitro cytotoxicity assay showed that EGNP
effectively inhibited the growth of A549 and H226 cells in a dose-dependent manner. In vivo biocompatibility study
showed that both GNP and EGNP did not activate the inflammatory response and had a low propensity to cause
immune response. Additionally, EGNP maintained a high therapeutic concentration in lungs throughout up to 24 h
comparing to that of free drug and GNP, implying the effect of ligand-targeted tumor delivery. Mice treated with
EGNP remarkably suppressed the tumor growth (~90% tumor inhibition) with 100% mice survival rate. Furthermore,
inhalation of EGNP resulted in elevated levels of cleaved caspase-3 (apoptotic marker), while MMP-9 level
significantly reduced comparing to that of control group.
Conclusions: Overall, results suggest that EGF surface-modified nanocarriers could be delivered to lungs via
inhalation and controlled delivery of drugs in the lungs will greatly improve the therapeutic options in lung cancer
therapy. This ligand-targeted nanoparticulate system could be promising for the lung cancer treatment.
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Lung cancer is one of the leading causes of cancer mortality
in developed and underdeveloped countries, and respon-
sible for 25% of death due to cancer [1]. The death rate due
to lung cancer precedes the number of death due to colo-
rectal, breast, prostate and pancreatic cancers [2]. Lung
cancer can be broadly divided into small cell lung cancer
and non-small cell lung cancer (NSCLC) with latter consti-
tutes nearly 80% of lung cancer mortality. Besides, these* Correspondence: fangshi@mail.sysu.edu.cn
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unless otherwise stated.cancers metastasizes by migrating to blood circulation,
from where it invade slowly into pulmonary capillaries and
surrounding tissues and regenerate secondary cancer sites
[3]. Presently, conventional treatment modalities such as
surgical resection, radiotherapy and chemotherapy are
standard treatment regimen to for lung cancers. However,
surgical removal of cancerous tissues is highly difficult in
many cases; radiotherapy damages the normal healthy cells
surrounding the cancer cells, and chemotherapy requiring
high dose level of individual drugs to treat lung carcinoma
[4]. Specifically, chemotherapy which is popularly employed
to treat cancer is rarely successful due to the less amount of
drug available in lung tissue even if administered at high
doses. Most of the times, chemotherapeutic drugs acttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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side-effects, and remains far from satisfactory [5]. There-
fore, a strong need to develop a therapeutic approach that
can increase the efficiency and minimize the adverse effects
continuously persists.
In this regard, a therapeutic strategy wherein antican-
cer drugs are directly delivered into the lungs would be
of significant importance. Inhaled delivery system is re-
ported to improve the local drug concentration in lung
tissues comparing to that of systemically administered
drugs [6-8]. The lung offers high absorption and surface
area (100 m2) such that drug can be rapidly absorbed,
rapid onset of action, high local concentration, and most
importantly it can minimize the systemic absorption of
drug and so are the reduced side-effects [9]. Although,
administration of free drug (via inhalation) enhanced the
therapeutic efficacy, however is associated with unwanted
toxicity to normal cells in the region. Therefore, develop-
ment of safe delivery system than can release the thera-
peutic moiety in a sustained manner to cancer cells while
at the same limit its exposure to healthy cells has stimu-
lated a great interest among researchers [10,11]. In this re-
gard, novel drug delivery system such as polymeric or lipid
nanoparticles has been successfully developed as part of
biopharmaceutical and formulation advancements [12,13].
Moreover, application of nanoparticles to tumors can be
further improved by conjugating some active targeting
moiety. The active targeting ligand allows the more specific
recognition, preferential interaction with cancer cells,
and high accumulation of drug in cancer tissues with
low/limited presence in normal cells, thereby enhancing
the clinical treatment of solid tumors [14,15]. In the
present study, gelatin nanoparticles (GNP) was prepared
and conjugated with epidermal growth factor (EGF) as an
active targeting moiety. EGF was selected as a targeting
ligand due to the overexpression of epidermal growth
factor receptor (EGFR) in most of the tumors, specific-
ally on NSCLC [16]. Doxorubicin (DOX), an anthracy-
cline antibiotic, was selected due to its broad spectrum
of action against lung cancers [17].
Present study aimed at treating lung cancers by the inhal-
ation of DOX-loaded EGF-conjugated gelatin nanoparticles
(EGNP) by nebulizer technique. We hypothesized that pul-
monary delivery of EGNP will allow better intratumoral
administration of DOX-loaded nanotherapeutics resulting
in superior anticancer efficacy. For this purpose, we devel-
oped gelatin nanoparticles (GNP) which was surface modi-
fied with NeutrAvidin-biotinylated epidermal growth factor
(bEGF) to facilitate EGFR-mediated endocytosis in tumor
cells (NSCLC). Various physicochemical and biological
experiments were performed to prove our hypothesis.
Additionally, in vivo studies have been conducted in
A-549 cancer cell bearing nude mice to systemically
evaluate the antitumor efficacy.Results and discussion
Formulation and characterization of EGF-conjugated
gelatin nanoparticles
Inhalation of anticancer drugs directly into the lungs
could result in high localization of therapeutic moiety
and can greatly improve the chemotherapy against sensi-
tive and resistant lung cancers. However, direct exposure
of free drug usually associated with severe side-effects in
non-cancerous health cells of the body [18]. Therefore,
focus was made to specifically kill the cancer cells while
sparing the normal cells. Recently, increased attention has
been paid for the development of inhalable drug delivery
systems which can release the chemotherapeutic drug in a
sustained manner in the local region. This approach was
further improved by conjugating an active targeting ligand
to the delivery vehicle which will be specific only to the
cancer cells in a receptor-mediated pathway. Such system is
expected to release its therapeutic load in the lungs either
within the tumor microenvironment or within the cancer
cells [16]. To this end, GNP was prepared by a two-step
desolvation method by evaporating the organic solvent.
The DOX-loaded nanoparticle was then surface modi-
fied NeutrAvidin-biotinylated-EGF conjugation (EGNP)
(Figure 1a). The natural gelatin is abundant in free amino
(−NH2) group which was employed to chemically conju-
gate with EGF. For this first, free amino group of gelatin was
converted to thiol group by reacting with 2-iminothiolane.
This thiol was then reacted with activated NeutAvidin
of EGF chain.
The particle size of nanoparticles plays an important
role in the intratumoral distribution and cellular intern-
alization. It has been reported that smaller nanoparticles
have greater access to the tumor region in the lungs. In
the present study, dynamic light scattering (DLS) analysis
showed a nanosized particle for EGNP (~120 nm) with a
narrow dispersity index (Figure 1b). The particle size was
again confirmed with transmission electron microscope
(TEM) and atomic force microscopy (AFM). TEM image
showed a black spherical particle which was uniformly dis-
persed on the copper-coated carbon grid. Moreover, the
TEM size was consistent with the DLS measurement and
no discrepancy was observed in the dried state (Figure 1c).
The surface topography was further confirmed by the AFM
analysis which exhibited a flat circular particle on the mica
surface (Figure 1d). The particles were distinguishly separate
from one another and maintained their size and shape. The
particles are flatted on the mica surface owing to the strong
physical interaction between each other. Furthermore, en-
trapment efficiency was observed to be more than 90% with
an effective loading capacity of ~20%.
In vitro drug release
The release profile of DOX from GNP and EGNP was
performed in phosphate buffered saline (pH 7.4). As can
Figure 1 Physicochemical characterization of nanoparticles. (a) Schematic presentation of EGF-conjugated gelatin nanoparticles (GNP).
DOX-loaded gelatin nanoparticle was formed which was then surface modified with NeutrAvidin-biotinylated-EGF complex to result EGF-conjugated
gelatin nanoparticles (EGNP) (b) Particle size distribution of EGNP (c) TEM mage of EGNP (d) AFM image of EGNP.
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observed from both the nanoparticulate system, followed
by a sustained release of drug (~70%) towards the end of
48 h of study period. Importantly, no difference in release
pattern were observed between GNP and EGNP indicating
that substitution or presence of EGF moiety on the nano-
particle surface did not deter the drug release from the de-
livery system. The release kinetics was confirmed by fitting
into four mathematical models including zero order, first
order, Higuchi and Korsmeyer–Peppas model. Of all this
model, Higuchi model (r = 0.998) best fitted the releaseFigure 2 Drug release and cellular uptake study. (a) In vitro release stu
phosphate buffered saline (pH 7.4) at 37°C. The samples were collected at spe
(b) Cellular uptake efficiency of GNP and EGNP in A549 and H226 cancer cells
min and analysed using HPLC method.*p < 0.05 is the statistical difference beprofile indicating a diffusion based release. To describe
drug release mechanism more precisely, semi-empirical
formula, called the Korsmeyer-Peppas power law was
employed. The exponent value of 0–0.4 indicates the
fickian diffusion while 0.4-0.89 indicates the non-fickian
release characteristics. In the present study, an ‘n’ value
of 0.68 clearly suggests a non-fickian mode of release
and diffusion and erosion being the main mechanism of
action. Such a controlled release system by which the
drug will be available to the tumor tissue in a constant
manner is of significant importance.dy of DOX from GNP and EGNP. The release study was performed in
cified time points for up to 48 h and analysed by spectrophotometer.
. Cells were incubated with 20 μg/ml (DOX equivalent) for 30 and 120
tween EGNP and GNP.
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In order to DOX within the cancer cells, the nanoparticles
have to be internalized into the cells wherein the drug is
released and available for its pharmacological action. In
this study, we have performed the cellular uptake in two
different lung cancer cell lines A549 and H226. The final
concentration of DOX exposed to cells was 20 μg/ml and
cell uptake was observed at 30 and 120 min. GNP and
EGNP were readily internalized in both the cell lines in a
time dependent manner (Figure 2b). EGNP showed 2-fold
higher cellular internalization than comparing to GNP in
A549 and H226 cell lines. The remarkable uptake of EGNP
was attributed to the receptor-mediated endocytosis. The
presence of EGF on the nanoparticle surface got specific
affinity towards EGFR receptors which are overexpressed in
both the lung cancer cell lines [19]. On the other hand
GNP follows a non-specific adsorption or non-specific
interaction with the cells resulting in markedly lower up-
take by comparison to ligand-conjugated nanocarriers
[20]. Therefore, it can be expected that EGF guidance
will allow the specific interaction of carrier to the cancer
cells leading to enhance antitumor response.
In vitro cytotoxicity analysis
The in vitro cytotoxicity analysis was carried out in
A549 and H226 cell lines (MTT assay). Free DOX, GNP
and EGNP was exposed to these cell lines and incubated
for 24 h and dose–response curve was developed. As
can be seen, all the therapeutic formulations showed a
concentration-dependent cytotoxicity in A549 and H226
cancer cell lines (Figure 3a,b). The difference in cytotox-
icity between these cell lines was attributed to the different
biological origin and presence of different level of drug-
resisting receptors (such as p-glycoprotein). Specifically,
EGNP showed the maximum antiproliferative effect in
these cell lines comparing to that of free DOX and GNP.Figure 3 Cytotoxicity analysis of nanoparticles. In vitro cytotoxicity ana
viability assay was performed by MTT assay. The cells were seeded at a den
exposure of respective formulations for 24 h at 37°C. The IC50values wereConsistently, IC50 value of EGNP was significantly
lower than other two formulations in these cell lines
(0.56 μg/ml and 0.47 μg/ml in A549 and H226 cells). The
enhanced cell killing effect of EGNP was in accordance
with the enhanced cellular uptake for this group. The
nanoparticles after the endocytosis uptake will immedi-
ately escape the endocytic compartments and reach the
acidic lysosome wherein drug will be released continu-
ously which diffuse into the nuclear core complex [21].
DOX acts by binding with the topo-isomerase enzyme,
intercalate the DNA, and arrest the cell growth. It can be
expected that at longer incubation (24 h) time, sub-G1
phase population might decrease, while the G2/M phase
population might be increased. Simultaneously, apoptotic
and necrotic cells and cell debris can be detected as a
“sub-G1” population [22]. It can be safely expected that
overexpression of EGFR in cancer cells might provoked
the preferential uptake of nanoparticles that resulted
in the superior anticancer activity.
In vivo biocompatibility of nanoparticles
An ideal delivery system is the one which can target the
anticancer drugs to the tumor interstitial spaces while
being non-toxic to normal cells. In this regard, biocompati-
bility of GNP and EGNP was studied in mouse model.
For this purpose, blank NPs were administered by in-
halation then mice were sacrificed at respective time
intervals (day 1, 4, and 7). Firstly, oxidative stress was
evaluated by assaying the total glutathione levels in the
homogenized lung samples. LPS was used as a positive
control which is known to induce the oxidative stress in the
lungs. As is seen, glutathione levels were remarkably in-
creased in all the formulations at day 1, possibly attributed
to the invasive nature of nanoparticles administration
(Figure 4a). However, in case of GNP and EGNP, gluta-
thione level continues to decrease until day 7. This waslysis of free DOX, GNP, and EGNP on (a) A549, (b) H226 cell lines. Cell
sity of 10000 cells per well and incubated overnight prior to the
calculated by GraphPad Prism using nonlinear regression analysis.
Figure 4 In vivo biocompatibility of nanoparticlesIn vivo biocompatibility of nanoparticles. (a) Glutathione level estimation in lung tissue
collected from mice treated with single dose inhalation. Lungs were harvested at day 1, 4, and 7 post treatments with GNP, EGNP, and
lipopolysaccharide. (b) IL-6 level estimation in lung tissue collected from mice treated with single dose inhalation. At respective days BAL fluid
was collected and processed. ***p < 0.0001 is the statistical difference between EGNP and control (LPS).
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showed a remarkable increase in the biomarker level.
Subsequently, IL-6 levels in bronchoalveolar lavage
(BAL) fluid samples were estimated at respective days
as mentioned above. As expected, IL-6 levels were sig-
nificantly high in LPS treated group than comparing to
either GNP or EGNP treated groups (Figure 4b). IL-6
acts as both a pro-inflammatory and anti-inflammatory
cytokine, and is secreted by T-cells and macrophages
to stimulate an immune response during infection and
after tissue trauma was also investigated as a marker of
immune response [23]. Therefore, results indicate that
either GNP or EGNP did not activate the inflammatory
response and had a low propensity to cause immune
response even when delivered directly into the lung tissues.
Generally, exposure of inhaled nanoparticles to lungs leads
to a range of inflammation and macrophages reactions and
activation of immune system. Present study however
showed a relatively low toxicity response of the lungs
to pulmonary nanoparticles indicating that the delivery
carrier is highly biodegradable and biocompatible. Such a
biocompatible and biodegradable delivery system could be
significant importance in the local delivery to lungs.
DOX concentration following pulmonary administration
For the effective anticancer therapy, a constant exposure
of DOX from nanoparticle is desired. For this purpose,
DOX concentration in lungs following pulmonary ad-
ministration was evaluated. As can be seen (Figure 5),
approximately ~1.5 μg/g of lung was observed following
the administration of free drug, while GNP did not increase
the DOX concentration beyond a limit. In contrast,
EGNP significantly maintained a high DOX concentra-
tion (~5 μg/g of lung) in the lungs following the pul-
monary administration in 30 min. There was literally noimprovement in the DOX level from GNP and free drug
even after 12 h of inhalation, while EGNP still maintained
higher drug concentration indicating that EGF surface
modification facilitated the accumulation of drug in the
tumor region. Surprisingly, EGNP treated group remark-
ably maintained a higher lung concentration even after
24 h of administration of formulations. It has been reported
that NSCLC cells overexpress the EGFR receptor which
got specific affinity towards the EGF moiety. From this
finding, it would be safe to confirm that GNP/EGNP
which was nebulized into minidroplet of a suitable mass
and aerodynamic diameter could easily escape the muco-
ciliary clearance to lower respiration track. This tendency
agrees with our intratumoral distribution pattern which
showed markedly higher fluorescence intensity. Data sug-
gests that the DOX liberated from the gelatin nanoparti-
cles in a controlled and sustained manner such that a
constant level of drug is exposed to cancer cells. Results
further indicate that cancer cells overexpressed with EGFR
could be effectively recognized by EGF modified nanopar-
ticles leading a high cellular accumulation in cancerous
lungs. Besides, high accumulation in the lung cancers will
eventually avoid the systemic circulation that will result in
severe drug-related adverse effects.
In vivo anticancer efficacy
The antitumor efficacy of GNP and EGNP was evaluated
in A549 tumor cell bearing nude mice. All the formula-
tions were administered 4 times during first 2-weeks after
the onset of experiment at a dose of 5 mg/kg. As shown in
Figure 6a, the tumors in untreated controlled group grew
linearly, rapidly, and attained maximum tumor volume
(~900 mm3) at the end of study period. In contrast, mice
treated with formulations contracted the growth of tumor
in a remarkable way. Free DOX significantly suppressed
Figure 5 DOX concentration in lungs following a single dose inhalation of free DOX, GNP, and EGNP. The DOX concentration in lungs
was determined after 0.5, 12, and 24h dose administration. The DOX from EGNP was significantly (p < 0.001) higher than GNP and free DOX.
**p < 0.001 is the statistical difference between EGNP and GNP.
Figure 6 In vivo antitumor efficacy study in A549 cells bearing xenograft tumor model after intranasal treatment of free DOX, GNP,
and EGNP. (a) In vivo anti-tumor effects (b) lung tumor mass (c) body weight changes (d) survival rate of mice. Each data point was
represented as mean ± sd (n = 4). ***p < 0.0001 is the statistical difference between EGNP and control. **p < 0.001 is the statistical difference
between EGNP and GNP.
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attained a final tumor volume of ~500 mm3. GNP on the
other hand does not improve the antitumor effect to a
great extent and the tumor volume grew linearly along
with free DOX group. As expected, EGNP showed the
maximum tumor suppression comparing to that of either
free DOX or GNP. The final tumor volume of GNP and
EGNP stood at 400 mm3 and 150 mm3, respectively.
Throughout the study period, EGNP maintained a constant
tumor volume and showed almost 90% tumor regression in
this group. When tumor volumes are normalized, EGNP
showed less than 2-fold increase in overall tumor volume
which is significantly less than control group where final
tumor volume increased up to 20-fold. Consistent with the
maximum tumor regression in EGNP treated mice group,
it showed a smallest tumor (~0.2g) while control group
showed the largest tumor size (~0.8g) (Figure 6b). The
tumor from free DOX and GNP groups were insignificantly
different. This tendency agrees with our previous result that
EGNP preferentially accumulated in the cancer cells
than comparing to other formulations. Additionally,
EGNP treated group remarkably maintained a higher
lung concentration even after 24 h of administration of
formulations. Results further indicate that cancer cells
overexpressed with EGFR could be effectively recog-
nized by EGF modified nanoparticles leading a high
cellular accumulation in cancerous lungs [16].
Changes in body weight of mice were regarded as the
indicator of safety profile. As seen from Figure 6c, none
of the group showed any reduction in body weight indi-
cating that DOX at a dose of 5 mg/kg was well tolerated.
Furthermore, sustained release from nanocarriers also
prevented the overexposure of drug to the normal cells.
The slight increase in the body weight of control mice
was attributed to the large tumor/tumor volume. The
median survival time of EGNP administered group was
100% which is superior to any other groups (Figure 6d).
As expected, untreated group showed lowest survival
rate with only 20% of mice were alive at the end of study
period. Similar trend was observed in DOX treated group.
Such low survival rate could be due the toxicity as well as
the inefficiency to control tumor growth.
Histopathological and Immunohistochemical analysis
H&E staining was performed on the respective tumors
to observe the histological changes in the cancer cells.
As can be seen (Figure 7a), control tumor exhibited a
dense extracellular network which was in turn divided
into the mini-compartments. Whereas, these extracellular
networks were missing in GNP and EGNP treated group
indicating its strong antitumor potential in the lungs.
Immunohistochemical analysis was performed to deter-
mine the apoptosis markers such as caspase-3 and MMP-9.
IHC analysis of lung section showed that caspase-3 levelsignificantly increased in formulation treated group com-
paring to that of control (Figure 7b). Specifically, EGNP
showed 4-fold increase in caspase-3 than that of control
group. Similarly, epithelial and mesenchymal transition
(EMT) changes in tumor sections were carried out by west-
ern blot analysis. As is seen, inhalation of GNP and EGNP
significantly reduced the expression of MMP-9 (Figure 7c).
Especially, EGNP showed a 5-fold reduction in MMP-9
comparing to that of control group indicating its superior
performance in the treatment of lung tumors. Overall, IHC
analysis showed that elevated level of cleaved caspase-3 was
in accordance with the superior anticancer efficacy follow-
ing the inhalation of dosage forms for 3 weeks (Figure 7d).
Furthermore, decreased MMP-9 levels reinforce the anti-
proliferative effects of DOX-loaded formulations.
Overall, our inhalation studies suggest a significant
reduction in lung tumor weight in EGNP treated group
compared to control group. The superior performance
of EGF-modified nanocarriers in cancerous tissues was
attributed to the EGFR receptor targeting (receptor-
mediated interactions). Secondly, better intratumoral
distribution restricted its entry into systemic circulation
their by maximizing its anticancer effect on cancerous tis-
sues. Thirdly, high intracellular accumulation for prolonged
period of time (24 h) and sustained drug release pattern will
allow a constant exposure of drug to the cancer cells. It has
been reported that nearly 70% of inhaled particles deposit
in the respiratory tract [24,25]. Therefore, a carefully de-
signed delivery system by inhalation will greatly improve
the chemotherapy efficiency. Importantly, EGF conjugation
will greatly increase the specificity towards the lung cancer.
Conclusion
In summary, we have successfully developed EGF-surface
modified gelatin nanoparticles to target EGFR overexpress-
ing lung cancers. The DOX-loaded nanoparticulate systems
were administered by inhalation to increase the therapeutic
effect of drug and to reduce its unwanted side effects.
The EGNP showed significantly high intracellular ac-
cumulation in A549 and H226 cell lines via a receptor
mediated endocytosis process. Consistently it showed a
remarkable intratumoral distribution in experimental
mice. GNP or EGNP did not activate the inflammatory
response and had a low propensity to cause immune
response indicating its high biocompatibility to lung
tissues. EGNP treated group maintained a remarkably
higher lung concentration even after 24 h of administration
of formulations. The in vivo anticancer experiment showed
that EGNP had a stronger tumor suppressive potential
(90%) by comparison to free DOX and GNP treated
group with 100% mice survival rate. IHC analysis of lung
section showed that EGNP inhalation significantly in-
creased the cleaved caspase-3 and MMP-9 levels reinfor-
cing the strong antiproliferative effects of DOX-loaded
Figure 7 Histopathological and Immunohistochemical analysis. (a) Representative histopathological images of tumor sections
(b) Immunohistochemical analysis of cleaved caspase 3 from tumor section collected from mice treated with GNP and EGNP
(c) Immunohistochemical analysis of MMP-9 is presented (d) Quantitative IHC analysis of cleaved caspase 3 and MMP-9 is also presented.
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to nanocarriers could effectively target the EGFR overex-
pressing lung cancers when administered by inhalation. This
ligand-targeted nanoparticulate system could be promising
for the lung cancer treatment.
Materials and methods
Materials
Gelatin type A (porcine skin, bloom strength 175) was
purchased from Sigma-Aldrich (China). Doxorubicin
was procured from Afine Chemicals Limited, China.
NeutrAvidin Fluorescein Conjugated (NeutrAvidinFITC),
m-Maleimidobenzoyl-N-hydroxy-sulfosuccinimide ester
(Sulfo-MBS), Sulfo-NHS-LC-biotin, 2-Iminothiolane.HCl,
D-Salt™ Dextran desalting columns and EZ™ BiotinQuantization Kit were purchased from Pierce (Rockford,
IL, USA). Human recombinant epidermal growth factor
(EGF) was purchased from BioSource (Camarillo, CA,
USA). All other chemicals were of reagent grade and
used without any modifications.
Methods
Preparation of doxorubicin-loaded gelatin nanoparticles
Gelatin nanoparticles (GN) were prepared as reported
previously [17]. Briefly, GN was prepared employing a
two-step desolvation method. 5 ml of 5% (w/v) of gelatin
solution was mixed with 5 ml of acetone containing
doxorubicin (10% w/w) and heated at 50°C. The precipitate
was again re-dispersed at 50°C. Glutaraldehyde (0.25%) was
added to cross-link the formed nanoparticle and stirred
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by vacuum drying, NPs were suspended in pure distilled
water. The resulting NPs were stored at 4°C until further
analysis or applications.
Preparation of EGF-surface modified gelatin nanoparticles
The surface modification of GN was done in two steps.
Firstly, free amino group on the GN was converted to
thiol groups by reacting with 2-iminothiolane. This thiol
group was used to conjugate the respective functional
group or ligand. For this, drug-loaded GN was dialyzed
against sodium phosphate buffer containing 10 mM
EDTA using a low molecular weight dialysis membrane.
Following which, 2-iminothiolane was reacted with GN
suspension for 2 h at 37°C to convert the amino group
into thiol group. The resulting NP product was washed
twice with sodium phosphate buffer containing 10 mM
EDTA to remove the unreacted materials. Separately,
NeutrAvidin (1 mg/ml) was mixed with Sulfo-MBS (2 mg)
in 1 ml of sodium phosphate buffer (pH 7.2) and to acti-
vate the functional group. The activated NeutrAvidin
was separated and purified using gel filtration column,
followed by mixing with thiolated GN and left to react
overnight at 4°C. The unbound biological moiety was
removed by centrifugation using a centrifugal filter de-
vice. In the second step, surface modified NeutrAvidin
was reacted with biotinylated EGF. For this, EGF was
dissolved in PBS buffer and then biotinylation reagent
was added and incubated for 1 h.
Particle size distribution and zeta potential
The liposome solutions were suitably diluted to analyse
the particle size distribution and zeta potential using dy-
namic light scattering (DLS) method. Malvern Zetasizer
(Malvern, UK) was used determine the DLS characteristics.
The samples were suitably diluted (200 μg/ml) with double
distilled water such that mean count rate will be around
300 kcps. All measurements were performed at a fixed
angle of 90° at 25°C room temperature. The results were
expressed as the size ± SD.
Loading efficiency
Loading efficiency was calculated from the total amount
of drug added versus amount of drug entrapped in the
nanoparticles. Briefly, drug-loaded complex was filtered
by Amicon centrifugal filter by centrifuging at a high
speed of 5000 rpm for 10 min. The filtrate was analyzed
for unentrapped drug by spectrometric method at 254
nm. A standard curve of DOX was plotted.Loading efficiency
Total amount of DOX – Amount of fr
Total weight of nanopartiMorphology
The morphological examination of Lipo-DTX and
Lipo-DTX/siRNA was carried out through a high resolution
transmission electron microscopy (TEM, JEM-2010HR).
Briefly, liquid sample was placed in a carbon coated
copper grid and counter stained with phosphotungistic
acid, followed by air drying for 2 h. The surface topography
was further confirmed by the atomic force microscopy
(AFM) where in samples were instilled on the mica surface
and air dried for 2 h.
In vitro release study
The release profile of DOX from GNP and EGNP was
monitored by means of dialysis method. In this study,
1ml of NP dispersions was placed in the dialysis bag
and both the borders were sealed with a dialysis clip.
The dialysis bag (molecular cut-off of 10 kD) was incubated
in 25 ml of release media (PBS, pH 7.4). The whole set up
was placed in an automated shaker maintained at 100 rpm
and 37°C. At predetermined time intervals, release media
was collected and replaced with equal amount of fresh
media. The released drug was quantified using a sophis-
ticated spectrophotometer (Shimadzu UV Spectrometer,
model mini1240) as mentioned above.
Cytotoxicity assay
The A549 and H226 cells were cultured in normal RPMI
media with 10% FBS and 100 units/mL penicillin, and
100 mg/ml streptomycin in 5% CO2 and 95% humidity
atmosphere in humidifier. The cell viability/cytotoxic po-
tential of individual formulation were performed by MTT
assay. Briefly, cells were seeded into 96-well plate at a seed-
ing density of 1 × 104 cells in 0.1 ml growth medium and
incubated for 24h. Following day, medium was removed
and cells were incubated with various concentrations of free
DOX, GNP and EGNP and incubated for 24 h. At each
time intervals, cells were washed with PBS and treated with
MTT solution (5 mg/ml in serum free media) and incu-
bated for 3 h. The purple blue formazan crystals were
extracted by the addition of DMSO. The optical density
was measured at 570 nm on a microplate reader.
Intracellular drug accumulation
The DOX accumulation in A549 and H226 cells were
quantified by HPLC method. For this, both the cells
were seeded in a 12-well culture plates at a density of
1 × 105 per well and incubated 18 h. The attached cells
were treated/exposed with free DOX, GNP, and EGNP
and incubated for 30 and 120 min. The cells wereee DOX  100
cles
Long et al. Journal of Nanobiotechnology 2014, 12:37 Page 10 of 11
http://www.jnanobiotechnology.com/content/12/1/37treated at a DOX concentration of 10 μg/ml. Cells were
washed twice with PBS and trypsinized. The trypsinized
cells were centrifuged; cell pellets were treated with lysis
buffer, and sonicated. The internalized drug was quanti-
fied by measuring the supernatant solutions via HPLC.
Animals
Female, 6-week old, athymic Nu/nu mice were used to per-
form the antitumor efficacy study. The animal studies were
approved by ‘Laboratory Animal Care’ and ‘Institutional
Animal Ethics Committee’, SUN Yat-Sen University, China.
The mice were caged in a pathogen free clean atmosphere
and maintained in 12 h day/light conditions. Animals
were maintained at standard conditions of 37°C and
60% humidity. Food and water were freely accessed to
all the animal groups’ throughput the study period.
Orthotopic tumor models
Prior to the cancer cell implantation, A-549 cells were
cultured in F12K media containing 10% FBS and 1%
penicillin-streptomycin antibiotic mixture. The orthotopic
tumor models were developed by anesthetizing the mice
with isoflurane, followed by a small skin incision was
made on the left part of chest (5 mm below the scapula).
A specialized Hamilton syringes with 28-gauge hypoder-
mic needles were used to instil the cell suspensions into
the left lung. At about 1.5 million A-549 cells (100 μl PBS)
were quickly injected at a depth of 3mm and immediately
syringe was removed. The wounds were surgically closed
with the help of skin clips. The animals were kept under
constant observation until the lung cancer develops.
Respective formulations were administered by inhalation.
The drug was administered at a dose of 5 mg/kg for 3
times at a gap of 3 days once. The lung weights and tumor
volume were used for assessment of therapeutic activity of
the treatments. At each time point, specified number of
mice was sacrificed, and lung tumor was isolated. The
tumor volume was measured using a Vernier calliper.
Antitumor efficacy was calculated by plotting the tumor
volume vs time for each formulation.
Histopathology analysis
The tumor samples were analysed by histopathological
staining. Briefly, 10 μm sections were deparaffinized and
rehydrated, and stained with Hematoxylin and Eosin stain.
Immunohistochemical analysis
The tumors were fixed with formalin and frozen until
further use. The samples were rehydrated by immersing in
the graded alcohol and embedded in paraffin. The paraffin
sections were cut into 10 μm thin sections and mounted
on a poly-L-lysine-coated slide. It was deparaffinized and
rehydrated through graded alcohol and incubated for 20
min with 3% hydrogen peroxide. Antigen retrieval forcleaved caspase-3 and MMP-9 staining was done with so-
dium citrate buffer for 10 min, followed by heated at 95°C
and cooled thereafter. Protein block solution was used
for 1h, followed by samples were stained and stained
with caspase-3 and MMP-9 antibodies. The samples were
exposed to substrate-chromogen to develop the color.
In vivo biocompatibility of nanoparticles
Six to eight week old female Balb/c mice was selected to
carry out the in vivo experiment. Firstly, mice were
treated with 50 μl of 1 mg/ml of respective GNP and
EGNP dispersions. Lipopolysaccharide was used as a
positive control which can induce acute lung injury. The
mice were sacrificed at day 1, 4, and 7 post-treatment
and lungs were surgically removed. The lung tissues
were homogenized and centrifuged and the supernatant
solution was deproteinated. The glutathione levels in the
supernatant were evaluated by glutathione assay kit as
per the instructions. IL-6 levels were determined from
the BAL fluid. The trachea was exposed from the mice
sacrificed at respective days. 1 ml of cold saline was injected
and immediately pulled back and collected. The cellular
materials were removed by centrifugation and the super-
natant was subjected to IL-6 assay by the IL-6 ELISA kit.
In vivo deposition of doxorubicin
Orthotropic tumor models were developed as men-
tioned above. The tumor mice were exposed to aerosol. A
nebulizer (AP-100100, APEX Medical Corp., Taiwan) was
used to generate aerosol particles. The free DOX, GNP, and
EGNP suspensions were used for the inhalation. The DOX
concentration deposited in the lung from different formula-
tions were measured. For this, mice were sacrificed at 0.5,
12, and 24 h post-treatment. The lung was carefully re-
moved and washed twice with PBS and soaked in 70% nitric
acid for 12-15 h. The organs were digested at 90°C for 2 h.
The organs were then homogenized, centrifuged, super-
natant was collected, and analyzed using HPLC method.
Statistical analysis
All data are expressed as mean ± standard deviation.
Statistical differences between groups were tested using
one-way analysis of variance (ANOVA). Statistical signifi-
cance was set in advance to a probability level of 0.05.
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